Medicus Pharma reports positive Phase 2 SKNJCT-003 Topline Data observing 73% Clinical Clearance and 40% Histological Clearance at day 57

The company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA